## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 26.8% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($53.58)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. HC Wainwright & Co. Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation**
- Source: Nasdaq | 20251203T050229 | Neutral | Relevance: 100%
- HC Wainwright & Co. has reiterated a Buy recommendation for Arrowhead Pharmaceuticals (ARWR) with an average one-year price target of $50.53/share, despite a projected decrease of 10.17% from its current price. The company's projected annual revenue is 410MM, a 50.51% decrease, and the non-GAAP EPS is expected to be -1.33. Institutional ownership of ARWR increased by 4.57% to 130,072K shares, and the put/call ratio of 0.32 suggests a bullish outlook.

**2. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry**
- Source: Simply Wall Street | 20251203T050228 | Somewhat-Bearish | Relevance: 100%
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw a 33% stock increase last month, culminating in a 116% rise over the past year, yet its price-to-sales (P/S) ratio of 9.2x remains below the industry average. Despite strong past revenue growth, future revenue is projected to contract by 14% annually, contrasting sharply with the broader biotech industry's anticipated 128% annual expansion. This outlook contributes to its modest P/S ratio, suggesting investors are cautious about future growth prospects.

**3. Arrowhead Pharmaceuticals Poised for Growth Following Breakthrough FDA Approvals**
- Source: StocksToTrade | 20251204T050229 | Bullish | Relevance: 96%
- Arrowhead Pharmaceuticals (ARWR) has seen significant growth following breakthroughs including an FDA Breakthrough Therapy designation for plozasiran and a milestone payment from Sarepta. The company reported a substantial revenue increase to $829.4M and a net profit of $30.1M, reversing previous losses. These developments, along with strategic collaborations, have boosted investor confidence and analyst price targets, positioning ARWR for continued expansion in the biopharmaceutical sector.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |
| 2025-12-01 | Chardan Capital | $60 | $60 | 0% |
| 2025-11-26 | Morgan Stanley | $48 | $45 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |
| 2025-12-01 | Chardan Capital | main | Buy |
| 2025-11-26 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 5 ($3.67M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Insider selling cluster: $3.7M in recent transactions.
2. Elevated short interest (9.8%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 7 raises (avg +38%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -31% YoY, concerning. Analyst sentiment positive (7 raises, avg +38%). Insider selling cluster ($3.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.7B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 29.9% to 26.8% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (26.8% > 10.0%), caution on chasing. MRS_5 at 0.1% confirms short-term momentum alignment. AM_20 at 29.4% shows strong absolute momentum above own 20MA. Outperforming sector by 29.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.96), confirming momentum. RSI overbought at 71, risk of mean reversion. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 26.77% (CS: 100) | Strong |
| RSI_14 | 70.6 | Overbought |
| MACD Histogram | 1.96 | Bullish |
| vs SMA20 | 1.294x | Above |
| vs SMA50 | 1.480x | Above |
| vs SMA200 | 2.609x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $61.44
- **Stop Loss:** $53.58 (12.8% risk)
- **Target:** $69.30 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 63
- **Position Value:** $3,870.72
- **Portfolio %:** 3.87%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*